GLP-1 receptor agonist
Semaglutide
Also known as Ozempic, Wegovy, Rybelsus
FDA-approved drugA GLP-1 receptor agonist and one of the most studied peptide medicines in the world.
Evidence
FDA-approved drug
Regulatory status
Prescription drug. FDA-approved for specific indications.
Class
GLP-1 receptor agonist
What it is
Semaglutide mimics GLP-1, a gut hormone involved in appetite, insulin release, and how quickly the stomach empties. It is a modified peptide designed to last about a week in the body.
What the research shows
- Large multi-year human trial programs (SUSTAIN for type 2 diabetes, STEP for weight management, SELECT for cardiovascular outcomes).
- FDA-approved brands cover type 2 diabetes, chronic weight management, and cardiovascular risk reduction in specific populations.
- The most common side effects reported in trials are gastrointestinal (nausea, constipation, diarrhea).
Read the published research on PubMed →
Researched for
Semaglutide is a prescription medicine approved only for specific uses. A licensed provider decides whether it is appropriate for you.
Educational content, not medical advice. This page does not recommend or dose any substance.
Related peptides
Dual GIP / GLP-1 receptor agonist
Tirzepatide
The first approved medicine that activates both the GIP and GLP-1 receptors.
FDA-approved drugTriple GIP / GLP-1 / glucagon receptor agonistRetatrutide
An investigational "triple agonist" currently in late-stage clinical trials.
Human clinical trialsLong-acting amylin analogCagrilintide
An amylin analog being studied alone and in combination with semaglutide.
Human clinical trials